Micro-cap stock $OMER soared on Monday amid heavy trading volume in response to its announcement of positive results from an open-label Phase 2 study evaluating lead product candidate OMS721 in patients with four different types of complement-associated kidney diseases: IgA nephropathy, membranous nephropathy, lupus nephritis and complement component 3 (C3) glomerulopathy. The data demonstrated statistically valid effects in key endpoints of improved renal function.